Collaborations & Alliances

Goodwin Biotech, Panacea in Monoclonal Antibody Alliance

To develop proof-of-concept conjugation for anti-cancer monoclonal antibody

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Panacea Pharmaceuticals has selected Goodwin Biotechnology to develop a proof-of-concept conjugation for a fully-human monoclonal antibody to an anti-cancer monoclonal antibody. The conjugate is labeled with indium‐111 (111In) and other potential radioisotopes for in vivo diagnostic imaging and treatment of cancers.   “Panacea has developed a fully human antibody directed against the tumor‐specific marker, human aspartyl (asparaginyl) β‐hydroxylase (HAAH),” said Dr. Steven A. Fuller, Ph.D., ch...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters